BONESUPPORT Q3 2026：固定汇率净销售+38%、SOLARIO研究登NEJM，斯德哥尔摩早盘大涨约17%

Tesla slips as group sets lower annual sales goal amid SpaceX merger talk
Introduction & Market Context
BONESUPPORT presented its third quarter 2026 results on October 22, showcasing strong financial performance and a major clinical milestone that sent shares surging 17% to $301 in early trading. The Swedish medical technology company reported net sales growth of 38% at constant exchange rates, driven by continued momentum for its CERAMENT G antibiotic-eluting bone graft product in the United States and solid recovery across European markets.
The presentation highlighted the publication of the SOLARIO clinical study in The New England Journal of Medicine, a landmark trial demonstrating that short-duration systemic antibiotic therapy is noninferior to long-duration treatment when combined with local antibiotic delivery. The study’s findings could significantly influence orthopedic infection treatment protocols while addressing growing concerns about antimicrobial resistance.
With shares trading near their 52-week high of $307, investors appear to be endorsing both the company’s commercial execution and the expanding clinical evidence supporting its antibiotic-eluting platform.
Quarterly Performance Highlights
BONESUPPORT’s third quarter financial results demonstrated accelerating growth and improving profitability across both major geographic markets. The following summary captures the quarter’s key achievements:
Net sales reached SEK 408.8 million compared to SEK 294.1 million in the prior year period, representing reported growth of 39% and constant currency growth of 38%. The adjusted operating result climbed to SEK 139.3 million from SEK 78.6 million, yielding an adjusted operating margin of 34%. Operating cash flow totaled SEK 137.8 million with a cash conversion rate of 99%, leaving the company with SEK 510.5 million in cash after executing a SEK 60 million share buyback.
The company’s last twelve months performance shows consistent upward momentum, as illustrated in the following chart tracking net sales growth by segment and quarter:
Total LTM net sales reached SEK 1,401 million, up 31% in constant currencies. Antibiotic-eluting CERAMENT products grew 39% at constant exchange rates on an LTM basis, while US CERAMENT bone void filler remained flat year-over-year in constant currency terms. The data demonstrates the company’s successful pivot toward higher-value antibiotic-eluting products that address bone infections alongside bone repair.
US Market Performance: CERAMENT G Drives Growth
The United States continued to serve as BONESUPPORT’s primary growth engine, with the region delivering strong performance across both new customer acquisition and deeper penetration of existing accounts.
US sales reached SEK 344.4 million in the third quarter, up 40% on a reported basis and 39% at constant exchange rates compared to SEK 246.3 million in Q3 2025. The company highlighted strong CERAMENT G performance across all market segments, with particular interest in revision arthroplasty and periprosthetic joint infections. The improved CMS reimbursement for CERAMENT G procedures, effective October 1, 2026, is expected to provide additional tailwinds, though management noted the impact would build gradually as hospitals update billing practices.
The following chart illustrates the consistent quarterly progression of CERAMENT G sales in the US market:
CERAMENT G quarterly sales in the US have grown from under $5 million in Q4 2022 to over $30 million in Q3 2026, with sales per working day exceeding $400,000. This steady upward trajectory reflects both expanding access to new hospital accounts and surgeons, as well as increasing adoption rates among existing users across trauma, foot and ankle, and arthroplasty applications.
EUROW Markets Show Broad-Based Strength
European and rest-of-world markets demonstrated robust recovery and expansion during the quarter, validating the company’s multi-channel go-to-market strategy.
EUROW sales totaled SEK 64.4 million, representing growth of 35% on a reported basis and 34% at constant exchange rates versus SEK 47.8 million in Q3 2025. Growth remained strong even after adjusting for distributor stocking orders from the new Australia and New Zealand partnership with Stryker. The company reported solid performance across direct markets, strong results in hybrid markets, and increased market share in distributor markets following focused investments. Positive feedback on the SOLARIO study at the combined EBJIS-MSIS meeting in Porto suggests growing clinical acceptance for the antibiotic-eluting approach.
Clinical Milestone: SOLARIO Study Published in NEJM
The publication of the SOLARIO study in The New England Journal of Medicine represents a significant validation of BONESUPPORT’s therapeutic approach and could influence treatment protocols for orthopedic infections globally.
The multicenter, open-label, noninferiority trial randomized 500 patients who underwent surgery for orthopedic infection and received local antibiotics to either long-duration (≥4 weeks) or short-duration (≤7 days) postoperative systemic antibiotic therapy. The primary analysis included 475 patients and demonstrated that definite treatment failure occurred in 11.1% of patients in the short-duration group compared to 14.1% in the long-duration group, meeting the prespecified noninferiority margin with a p-value of 0.324.
Beyond demonstrating comparable efficacy, the study revealed substantial patient benefits from shorter antibiotic courses, as shown in the following adverse event comparison:
By six weeks after surgery, symptoms potentially related to treatment occurred in just 17.2% of patients receiving short-duration antibiotics versus 45.2% in the long-duration group. This difference persisted at 3-6 months, with adverse event rates of 8.5% versus 20.4% respectively. The reduction in adverse events makes short-duration therapy significantly more patient-friendly while maintaining treatment effectiveness.
The study’s implications extend beyond individual patient outcomes to address the global challenge of antimicrobial resistance:
By shortening therapy duration from more than 4 weeks to less than 7 days while achieving 100% compliance, high-dose delivery, and precise targeting, the SOLARIO approach reduces total antimicrobial burden by 6.4 kilograms per 100 patients. These findings support the World Health Organization’s antimicrobial stewardship goals and could accelerate adoption of local antibiotic therapy in orthopedic infection management.
Financial Performance Analysis
The third quarter results demonstrated strong revenue growth drivers across both geographic segments, as illustrated in the following breakdown:
The SEK 114.7 million increase in net sales from Q3 2025 to Q3 2026 consisted of SEK 94.8 million from organic US growth, SEK 16.3 million from organic EUROW growth, and SEK 3.6 million from favorable foreign exchange effects. US growth of 40% (39% at constant exchange rates) and EUROW growth of 35% (34% at constant exchange rates) reflect balanced geographic expansion.
Detailed regional financial performance shows sustained high margins and improving contribution:
The US segment maintained a gross margin of 94.0% in Q3 2026 while growing contribution to SEK 171.4 million from SEK 111.2 million in Q3 2025. EUROW achieved an 81.9% gross margin with contribution of SEK 19.9 million versus SEK 12.5 million in the prior year period. The consistent high margins in both regions reflect the value proposition of BONESUPPORT’s differentiated antibiotic-eluting technology.
Operating Leverage and Profitability Trends
As BONESUPPORT scales its commercial operations, the company is demonstrating improving operating leverage and expanding profitability metrics, as shown in the following quarterly trend analysis:
Net sales growth of 39% significantly outpaced operating expense growth, driving the adjusted operating result to SEK 139.3 million and the adjusted operating margin to 34% in Q3 2026. The company maintained its gross margin at 92.0% despite some manufacturing cost pressures and tariff impacts. Operating cash flow of SEK 137.8 million represented 99% cash conversion, demonstrating the quality of earnings and efficient working capital management.
The progression of operating margin improvement illustrates the company’s path from heavy commercial investment to sustainable profitability:
The adjusted operating margin excluding foreign exchange effects reached 32.9% in Q3 2026, up from 28.6% in Q3 2025 and representing the highest level achieved to date. This improvement reflects the operating leverage inherent in the business model as revenue scales while the company maintains disciplined expense management. The USD exchange rate trend has also provided some tailwind to reported results.
Forward-Looking Statements and Guidance
BONESUPPORT maintained its full-year 2026 guidance while highlighting several catalysts for sustained growth:
The company reiterated its expectation for net sales growth of 33-36% at constant exchange rates for full year 2026. Key strategic priorities include continuing to drive CERAMENT G adoption in the US across trauma, foot and ankle, and arthroplasty applications; leveraging the SOLARIO publication to support clinical adoption; advancing the FDA De Novo process for CERAMENT V with a complete data package submitted; and preparing for entry into the spine market with both CERAMENT BVF and antibiotic-eluting products.
Management emphasized that the improved CMS reimbursement effective October 1, 2026 is expected to provide incremental benefit over time rather than an immediate fourth quarter impact, as hospitals gradually update billing practices and surgeons become familiar with the new codes. The company continues to invest in sales force expansion, hospital administrator outreach, and market access initiatives to support long-term growth.
The CERAMENT V FDA review process remains on track, with management expecting a formal response in late Q4 2026 or early Q1 2027. If approved, the product would provide surgeons with a higher-dose antibiotic option for more severe infections, with European experience suggesting CERAMENT V could represent 25-30% of antibiotic-eluting product mix over time while expanding the overall addressable market rather than simply cannibalizing CERAMENT G.
With shares trading at $301 following the presentation, near the 52-week high of $307, investors appear to be endorsing both the company’s near-term execution and its longer-term growth opportunities as clinical evidence supporting local antibiotic therapy continues to build.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.